TL;DR: The Centers for Medicare & Medicaid Services modified NCD 150 covering Anti-Inhibitor Coagulant Complex (AICC) for hemophilia patients, effective March 7, 2026. Here's what billing teams need to know.
CMS Anti-Inhibitor Coagulant Complex coverage policy under NCD 150 has been updated. This policy governs Medicare reimbursement for AICC — a clotting factor concentrate used in hemophilia A patients who have developed inhibitor antibodies to factor VIII. The policy does not list specific HCPCS or CPT codes in the current published version, which creates a real documentation and billing challenge you need to address now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Anti-Inhibitor Coagulant Complex (AICC) |
| Policy Code | NCD 150 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | High |
| Specialties Affected | Hematology, Hemophilia Treatment Centers, Infusion Therapy, Hospital Outpatient |
| Key Action | Audit all AICC claims for documentation of inhibitor antibody status and failure of less expensive therapies before March 7, 2026 |
CMS Anti-Inhibitor Coagulant Complex Coverage Criteria and Medical Necessity Requirements 2026
NCD 150 is the National Coverage Determination governing Medicare coverage of Anti-Inhibitor Coagulant Complex for hemophilia treatment. The Centers for Medicare & Medicaid Services classifies AICC under the Blood Clotting Factors for Hemophilia Patients benefit category. That classification matters because it determines how your MAC processes and adjudicates these claims.
The medical necessity criteria here are narrow and sequential. AICC is covered for Medicare beneficiaries with hemophilia A who have developed inhibitor antibodies to factor VIII, but only when two additional conditions are met. The patient must be experiencing a major bleeding episode, and they must have already failed to respond to other, less expensive therapies.
That step therapy requirement is the real pressure point in this coverage policy. CMS expects documented evidence that cheaper treatment options were tried first. If your claim hits a Medicare Administrative Contractor desk without that failure-of-prior-therapy documentation, expect a claim denial. This isn't a gray area — it's a hard sequential requirement written into the NCD.
Prior authorization requirements for AICC under Medicare fee-for-service are not explicitly addressed in NCD 150 itself. However, your MAC may have supplemental local coverage determination guidance layered on top of this NCD. Check with your specific MAC before assuming national coverage is sufficient for your claims. CMS billing guidelines rarely exist in isolation, and hemophilia treatment is exactly the kind of high-cost specialty area where MACs add requirements.
Medical necessity documentation needs to show three things clearly: the hemophilia A diagnosis with factor VIII inhibitor antibodies, the nature of the major bleeding episode, and the clinical rationale for why less expensive therapies failed or were contraindicated. Get all three in the record before billing.
CMS AICC Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Hemophilia A with factor VIII inhibitor antibodies — major bleeding episode, failed less expensive therapies | Covered | Not specified in NCD 150 | Step therapy documentation required; must show failure of prior therapies |
| Hemophilia A with factor VIII inhibitor antibodies — no documented failed prior therapy | Not Covered | Not specified in NCD 150 | Missing step therapy documentation will result in claim denial |
| Hemophilia B or other factor deficiencies | Not addressed in NCD 150 | Not specified in NCD 150 | Seek MAC-level LCD guidance; NCD 150 is specific to hemophilia A with factor VIII inhibitors |
| AICC as first-line treatment without documented major bleeding episode | Not Covered | Not specified in NCD 150 | Coverage requires major bleeding episode as a condition |
CMS Anti-Inhibitor Coagulant Complex Billing Guidelines and Action Items 2026
This policy modification becomes effective March 7, 2026. That's your hard deadline. Here's what to do before then.
| # | Action Item |
|---|---|
| 1 | Audit your current AICC claims documentation now. Pull any open or recently submitted AICC claims and verify that each one documents hemophilia A diagnosis, confirmed factor VIII inhibitor antibody status, a qualifying major bleeding episode, and failure of prior less expensive therapy. Missing any one of these elements is enough to trigger a claim denial under NCD 150. |
| 2 | Contact your MAC for local coverage determination guidance. NCD 150 sets the national floor for AICC billing. Your MAC may have an LCD that adds prior authorization requirements, specific HCPCS billing codes, or documentation templates. Get that information before March 7, 2026. Don't assume the NCD alone tells the whole story. |
| 3 | Build a documentation checklist for your clinical team. AICC billing failures almost always start at documentation, not at the claim itself. Work with your hematology or infusion team to create a pre-billing checklist that captures inhibitor antibody confirmation, bleeding episode severity, and the prior therapy failure narrative. This should be a standing order, not a one-time fix. |
| 4 | Flag the absence of specific codes in your charge capture system. NCD 150 as published does not list specific CPT or HCPCS codes. That creates a charge capture risk if your billing team is uncertain which codes to attach to AICC administration. Work with your billing consultant to confirm which HCPCS J-codes or Q-codes your MAC recognizes for AICC, and make sure those are what your system is submitting. Submitting the wrong code — even with perfect documentation — will cause a denial. |
| 5 | Review your hemophilia treatment center agreements. If you operate a designated hemophilia treatment center or contract with one, review how this policy modification changes your coverage documentation expectations. Reimbursement for high-cost clotting factors like AICC is under consistent scrutiny. Make sure your agreements and billing protocols align with the updated NCD 150 criteria. |
| 6 | Talk to your compliance officer if you're unsure how this applies to your patient mix. AICC is a high-cost drug, and Medicare scrutiny on clotting factor claims is real. If your practice or facility sees a significant volume of hemophilia A patients with inhibitors, loop in your compliance officer before the March 7, 2026 effective date to review your documentation practices and billing protocols. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Anti-Inhibitor Coagulant Complex Under NCD 150
A Note on Codes for This Policy
NCD 150 as published does not specify CPT, HCPCS, or ICD-10 codes. This is a real billing problem, not a formatting oversight.
AICC billing typically involves HCPCS J-codes or Q-codes for clotting factor products. The specific code depends on the product, the dosage, and what your MAC accepts. Using the wrong HCPCS code for an AICC product — even when clinical coverage criteria are met — is a common cause of denial.
Contact your MAC directly to confirm the current accepted HCPCS codes for AICC products under NCD 150. Also verify whether your MAC has a local coverage determination that supplements NCD 150 with code-level specificity. Do not infer codes from older claims without verifying they still apply under the modified policy.
ICD-10-CM Diagnosis Codes to Consider
NCD 150 does not list diagnosis codes. However, based on the coverage criteria — hemophilia A with factor VIII inhibitor antibodies — your clinical team should be coding with precision. The diagnosis must clearly establish hemophilia A with an inhibitor. Generic hemophilia coding without inhibitor specificity will undermine your medical necessity documentation.
Work with your coding team and clinical staff to confirm the ICD-10-CM codes that accurately reflect inhibitor-positive hemophilia A status. Your MAC guidance will be the authoritative source on which diagnosis codes align with NCD 150 claims.
The Real Issue with NCD 150's Lack of Specific Codes
Here's what makes this policy modification harder to manage than most: CMS published a substantive coverage policy with clear clinical criteria and no billing codes attached. That's not unusual for NCDs, but it does mean your billing team is doing extra work.
You're responsible for knowing which HCPCS codes your MAC accepts, which ICD-10-CM codes accurately capture the inhibitor-positive hemophilia A diagnosis, and how to tie clinical documentation to the coverage criteria. None of that is spelled out in NCD 150 itself.
This is exactly the pattern where claims leak through without anyone catching them. A patient qualifies clinically. The physician documents appropriately. But the billing code submitted doesn't match what the MAC expects, or the diagnosis code isn't specific enough to trigger coverage. The claim denies. Nobody connects the dots back to the NCD.
Build the cross-walk between NCD 150 coverage criteria and your specific billing codes before March 7, 2026. Don't wait for a denial pattern to surface.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.